ClinicalTrials.gg

Program

epaminurad

Also written as “Epaminurad 9 mg”, “Epaminurad 9 mg (JW Pharmaceutical)” and “Epaminurad 9 mg (Shanghai STA Pharmaceutical)”.

Its studies are mostly in Gout, led by JW Pharmaceutical.

Furthest: phase 3, since Feb 27, 20235 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
JW Pharmaceutical50 open or runningphase 3since Feb 27, 2023Feb 27, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2023First study: phase 3 study in GoutFirst studyNCT05815901 · 612 enrolled · South Korea
  2. May 24, 2024Phase 1 study in HealthyNCT06435442 · 57 enrolled · South Korea
  3. Oct 28, 2024Phase 1 study in Healthy VolunteersNCT06665425 · 18 enrolled · South Korea
  4. Jun 16, 2025Phase 1 study in Healthy Male AdultsNCT07036458 · 8 enrolled · United Kingdom
  5. Jan 1, 2026Phase 1 study in HealthyNCT07374406 · 34 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07374406Healthy · South Korea1CompletedFeb 19, 202634
NCT07036458Healthy Male Adults · United Kingdom1CompletedSep 5, 20258
NCT06665425Healthy Volunteers · South Korea1CompletedMay 2, 202518
NCT06435442Healthy · South Korea1CompletedDec 30, 202557
NCT05815901Gout · South Korea3CompletedMar 26, 2024612

How it is read

Names in the registry

  • “Epaminurad 9 mg”, 2 entries
  • “Epaminurad 9 mg (JW Pharmaceutical)”, 1 entry
  • “Epaminurad 9 mg (Shanghai STA Pharmaceutical)”, 1 entry
  • “Epaminurad 6 mg”, 1 entry
  • “14C Epaminurad Oral Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.